Measuring HIV Neutralization in a Luciferase Reporter Gene Assay
- David C. Montefiori
- … show all 1 hide
Purchase on Springer.com
$49.95 / €39.95 / £34.95*
* Final gross prices may vary according to local VAT.
Neutralizing antibody (NAb) assays for human immunodeficiency virus (HIV) are used to study the immune response in infected individuals, to examine monoclonal antibodies and viral diversity, and to judge the potential value of candidate vaccine immunogens in preclinical and clinical trials. An important aspect of these efforts is an ability to achieve and document equivalent assay performance across multiple laboratories. Recent advances in assay technology have led to major improvements in how HIV NAbs are measured. Stable cell lines containing HIV Tat-regulated reporter genes are now available that permit rapid, sensitive and reproducible measurements of virus neutralization after a single round of infection in a high throughput format.Moreover, these assays may be used with molecularly cloned Env-pseudotyped viruses for greater reagent stability and traceability.A luciferase (Luc) reporter gene assay performed in TZM-bl (JC53bl-13) cells was recently optimized and many of its performance parameters have been validated. This assay has become the main endpoint neutralization assay used by the NIH-sponsored HIV Vaccine Trials Network and by a growing number of laboratories worldwide.
- Wyatt, R., Sodroski, J. (1998) The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280, 1884–1888. CrossRef
- Lasky, L. A., Nakamura, G., Smith, D. H., et al. (1987) Delineation of a region of the human immunodeficiency virus gp120 glycoprotein critical for interaction with the CD4 receptor. Cell 50, 975–985. CrossRef
- Berger, E. A. (1997) HIV entry and tropism: the chemokine receptor connection. AIDS 11(suppl. A), S3–S16.
- Berger, E. A., Doms, R. W., Fenyö, E.-M., et al. (1998) A new classification for HIV-1. Nature 391, 240. CrossRef
- Weissenhorn, W., Dessen, A., Harrison, S. C., et al. (1997) Atomic structure of the ectodomain from HIV-1 gp41. Nature 387, 426–430. CrossRef
- Chan, D. C., Fass, D., Berger, J. M., et al. (1997) Core structure of gp41 from the HIV envelope glycoprotein. Cell 89, 263–273. CrossRef
- Chan, D. C., Kim, P. S. (1998) HIV entry and its inhibition. Cell 93, 681–684. CrossRef
- Salzwedel, K., Smith, E. D., Dey, B., et al. (2000) Sequential CD4-coreceptor interactions in human immunodeficiency virus type 1 Env function: soluble CD4 activates Env for coreceptor-dependent fusion and reveals blocking activities of antibodies against cryptic conserved epitopes on gp120. J. Virol. 74, 326–333. CrossRef
- McDougal, J. S., Kennedy, M. S., Orloff, S. L., et al. (1996) Mechanism of human immunodeficiency virus type 1 (HIV-1) neutralization: irreversible inactivation of infectivity by anti-HIV-1 antibody. J. Virol. 70, 5236–5245.
- Sullivan, N., Sun, Y., Sattentau, Q., et al. (1998) CD4-induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization. J. Virol. 72, 4694–4703.
- Wei, X., Decker, J. M., Wang, S., et al. (2003) Antibody neutralization and escape. Nature 422, 307–312. CrossRef
- Platt, E. J., Wehrly, K., Kuhmann, S. E., et al. (1998) Effects of CCR5 and CD4 cell surface concentrations on infection by macrophage tropic isolates of human immunodeficiency virus type 1. J. Virol. 72, 2855–2864.
- Wei, X., Decker, J. M., Liu, H., et al. (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother. 46, 1896–1905. CrossRef
- Leitner, T., Korber, B., Daniels, M., et al. (2005) HIV-1 subtype and circulating recombinant form (CRF) reference sequences, 2005. in (T. Leitner, B. Foley, B. Hahn, P. Marx, F. McCutchan, J. W. Mellors, S. Wolinski, and B. Korber eds.), HIV Sequence Compendium 2005, pp. 41–48. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, N. Mex. (http://hiv.lanl.gov).
- Kwong, P. D., Doyle, M. L., Casper, D. J., et al. (2002) HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420, 678–682. CrossRef
- Richman, D. D., Wrin, T., Little, S. J. et al. (2003) Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. (USA) 100, 4144–4149. CrossRef
- Haynes, B. F, Montefiori, D. C. (2006) Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Rev. Vaccines 5, 347–363. CrossRef
- Mascola, J. R., D’Souza, P., Gilbert, P., et al. (2005) Recommendations for the design and use of standard virus panels to assess the neutralizing antibody response elicited by candidate human immunodeficiency virus type 1 vaccines. J. Virol. 79, 10103–10107. CrossRef
- Li, M., Gao, F., Mascola, J. R., et al. (2005) Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79, 10108–10125. CrossRef
- Li, M., Salazar-Gonzalez, J. F., Derdeyn, C. A., et al. (2006) Genetic and neutralization properties subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in southern Africa.. J. Virol., in press.
- Brown, B. K., Darden, J. M., Tovanabutra, S., et al. (2005) Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 (HIV-1) isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines. J. Virol. 79, 6089–6101. CrossRef
- Esparza, J. and the Coordinating Committee of the Global HIV/AIDS Vaccine Enterprise. (2005) The Global HIV/AIDS Vaccine Enterprise: Scientific strategic plan. PLoS Medicine 2(2), e25.
- Johnson, V. A., Byington, R. E. (1990) Infectivity assay (virus yield assay), in (Aldovani, A., and Walker, B. D., eds.), Techniques in HIV Research, pp71–76. Stockton Press, New York, N.Y.
- Montefiori, D. C., Cornell, R. J., Zhou, J. Y., et al. (1994) Complement control proteins, CD46, CD55 and CD59, as common surface constituents of human and simian immunodeficiency viruses and possible targets for vaccine protection. Virology 205, 82–92. CrossRef
- Louder, M. K., Sambor, A., Chertova, E., et al. (2005) HIV-1 envelope pseudotyped viral vectors and infectious molecular clones expressing the same envelope glycoprotein have a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is associated with decreased neutralization sensitivity. Virology 339, 226–238. CrossRef
- Measuring HIV Neutralization in a Luciferase Reporter Gene Assay
- Book Title
- HIV Protocols
- Book Part
- Section IV
- pp 395-405
- Print ISBN
- Online ISBN
- Series Title
- Methods In Molecular Biology™
- Series Volume
- Series ISSN
- Humana Press
- Copyright Holder
- Humana Press
- Additional Links
- Neutralizing antibodies
- HIV vaccines
- reporter gene
- assay standardization
- Industry Sectors
To view the rest of this content please follow the download PDF link above.